Relatlimab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Relatlimab
Accession Number
DB14851
Type
Biotech
Groups
Investigational
Description

Relatlimab is under investigation in clinical trial NCT02966548 (Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors).

Synonyms
  • BMS-986016
Categories
Not Available
UNII
AF75XOF6W3
CAS number
1673516-98-7

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Wikipedia
Relatlimab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Not Yet RecruitingTreatmentMelanoma1
1RecruitingOtherGlioblastomas1
1RecruitingTreatmentCancer, Advanced1
1RecruitingTreatmentEsophageal Cancers / Gastrooesophageal Cancer / Malignant Neoplasm of Stomach1
1RecruitingTreatmentMalignancies1
1, 2RecruitingTreatmentCancer, Advanced1
1, 2RecruitingTreatmentGastrooesophageal Cancer / Immune Checkpoint Inhibition1
1, 2RecruitingTreatmentNeoplasms by Site1
1, 2RecruitingTreatmentNeoplasms, Hematologic1
1, 2RecruitingTreatmentVarious Advanced Cancer1
2Active Not RecruitingTreatmentCancer, Advanced1
2Active Not RecruitingTreatmentMicrosatellite Stable Colorectal Cancer / Microsatellite Unstable Colorectal Cancer / Mismatch Repair Deficient Colorectal Cancer / Mismatch Repair Proficient Colorectal Cancer / MSI Negative Colorectal Cancer / MSI Positive Colorectal Cancer1
2RecruitingTreatmentAdvanced Gastric Cancer1
2RecruitingTreatmentAdvanced Melanoma / Metastatic Melanoma / Metastatic Melanoma Stratified by MHC-II Expression1
2RecruitingTreatmentCancer, Advanced1
2RecruitingTreatmentChordomas / Locally Advanced Chordoma / Metastatic Chordoma / Unresectable Chordoma1
2RecruitingTreatmentColorectal Adenocarcinoma / Microsatellite Stable (MSS) Colorectal Adenocarcinomas1
2RecruitingTreatmentCutaneous Melanoma / Melanoma / Mucosal Melanoma / Ocular Melanoma / Oligometastatic Melanoma / Stage III Acral Lentiginous Melanoma AJCC v7 / Stage IIIB Cutaneous Melanoma AJCC v7 / Stage IIIB Uveal Melanoma AJCC v7 / Stage IIIC Cutaneous Melanoma AJCC v7 / Stage IIIC Uveal Melanoma AJCC v7 / Stage IV Acral Lentiginous Melanoma AJCC v6 and v7 / Stage IV Cutaneous Melanoma AJCC v6 and v7 / Stage IV Uveal Melanoma AJCC v71
2RecruitingTreatmentMSI-H Tumors / Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy1
2RecruitingTreatmentMelanoma1
2, 3Active Not RecruitingTreatmentMelanoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:30 / Updated on May 21, 2019 12:30